Reaction

Product Packaging Confusion reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,402 reports · 32 co-occurring drugs

As of the last recalculation, Product Packaging Confusion appears in 2,402 FAERS reports alongside 32 co-occurring drug terms. The strongest observed disproportionality signal is UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE (PRR 122.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Umeclidinium Bromide And Vilanterol Trifenatate	215	122.4	124.0
Fluticasone Furoate And Vilanterol Trifenatate	179	46.5	46.7
Tranexamic Acid	25	24.6	24.7
Atropine Sulfate	24	19.4	19.5
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	74	15.9	16.0
Heparin Sodium	25	15.9	15.9
Umeclidinium	16	15.6	15.6
Methylprednisolone Acetate	14	15.2	15.3
Rocuronium Bromide	16	11.8	11.9
Atropine	11	11.6	11.6
Magnesium Sulfate In Water For	15	10.2	10.2
Magnesium Sulfate Heptahydrate	15	10.0	10.0
Magnesium Sulfate	15	10.0	10.0
Nirmatrelvir And Ritonavir	59	9.7	9.7
Chlorhexidine Gluconate	9	8.6	8.6
Amiodarone Hydrochloride	11	8.5	8.5
Bupivacaine	9	8.4	8.4
Norepinephrine Bitartrate	13	7.9	7.9
Sodium Chloride Tablet	65	7.8	7.8
Sodium Chloride Tablets	65	7.8	7.8
Sodium Chloride	67	7.5	7.5
Epinephrine	49	6.6	6.6
Indapamide	13	6.3	6.3
Adrenalinum	29	6.1	6.1
Fluticasone Propionate And Salmeterol	29	6.1	6.1
Triamcinolone Acetonide Ointment Usp, 0.05%	15	5.6	5.6
Insulin Human	25	5.5	5.5
Levetiracetam In Sodium Chloride	43	4.9	4.9
Levetiracetam Oral	43	4.9	4.9
Levetiracetam Injection	43	4.9	4.9
Triamcinolone Acetonide	16	4.5	4.5
Iohexol	3	3.1	3.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.